Literature DB >> 6819702

DNA-flow-cytometric measurements on the normal, atrophic, hyperplastic and neoplastic human endometrium.

G E Feichter, H Höffken, J Heep, D Haag, D Heberling, H Brandt, H Rummel, K Goerttler.   

Abstract

DNA distribution patterns and the fractions of the cell cycle phases were determined by means of flow-through cytometry in 87 samples of normal, atrophic, hyperplastic and carcinomatous human endometrium. The S-phase fractions vary during the normal menstrual cycle between 1 and 3% and reach a periovulatory maximum between 4.4 and 4.7%. Atrophic endometrium and regressive glandular cystic hyperplasia have little DNA synthesis (1.01% and 1.68% S-phase fractions respectively). Proliferating glandular cystic hyperplasia reveals 3.38% S-phase fraction, whereas adenomatous hyperplasia has an increased number of DNA-synthesizing cells (4.81%). The well-differentiated endometrial carcinoma shows no cytophotometrically detectable differences in comparison to adenomatous hyperplasia. All endometrial samples except for poorly differentiated endometrial carcinoma showed a diploid to tetraploid DNA distribution pattern. The poorly differentiated endometrial carcinoma displays two different types: one rapidly growing diploid-tetraploid tumor with 8.0 to 9.6% S-phase fractions, and another type with stemline deviations, polyploid nuclei and less pronounced synthetic activity.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6819702     DOI: 10.1007/bf00585613

Source DB:  PubMed          Journal:  Virchows Arch A Pathol Anat Histopathol        ISSN: 0174-7398


  12 in total

Review 1.  DNA in human tumors: a cytophotometric study.

Authors:  N Böhm; W Sandritter
Journal:  Curr Top Pathol       Date:  1975

2.  [Mitosis in the endometrium].

Authors:  C A AHRENS; G PRINZ
Journal:  Geburtshilfe Frauenheilkd       Date:  1957-05       Impact factor: 2.915

Review 3.  Recent advances in endometrial neoplasia.

Authors:  A Ferenczy
Journal:  Exp Mol Pathol       Date:  1979-08       Impact factor: 3.362

4.  [DNA content of normal, hyperplastic and malignant endometrium, determined cytofotometrically (author's transl)].

Authors:  H Sachs; E U wambach; K Würthner
Journal:  Arch Gynakol       Date:  1974

5.  Deoxyribonucleic acid content of presumed precursors of endometrial carcinoma.

Authors:  D Wagner; R M Richart; J Y Terner
Journal:  Cancer       Date:  1967-12       Impact factor: 6.860

6.  DNA content of human endometrial gland cells during the menstrual cycle.

Authors:  D Wagner; R M Richart; J Y Terner
Journal:  Am J Obstet Gynecol       Date:  1968-01-01       Impact factor: 8.661

7.  The synthesis of DNA and RNA in normal human endometrium in short-term incubation in vitro and its response to oestradiol and progesterone.

Authors:  S Nordqvist
Journal:  J Endocrinol       Date:  1970-09       Impact factor: 4.286

8.  Flow microfluorometric deoxyribonucleic acid (DNA) analysis supplementing routine histopathologic diagnosis of biopsy specimens.

Authors:  D Haag
Journal:  Lab Invest       Date:  1980-01       Impact factor: 5.662

9.  Mitosis counting--a need for reappraisal.

Authors:  P S Ellis; R Whitehead
Journal:  Hum Pathol       Date:  1981-01       Impact factor: 3.466

10.  Evaluation of flow cytometric data of human tumours. Correction procedures for background and cell aggregations.

Authors:  H P Beck
Journal:  Cell Tissue Kinet       Date:  1980-03
View more
  3 in total

1.  Steroid receptors and proliferative activity in non-neoplastic and neoplastic endometria.

Authors:  H Pickartz; R Beckmann; B Fleige; W Düe; J Gerdes; H Stein
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1990

Review 2.  Clinical and biological significance of aneuploidy in human tumours.

Authors:  M L Friedlander; D W Hedley; I W Taylor
Journal:  J Clin Pathol       Date:  1984-09       Impact factor: 3.411

3.  DNA ploidy, cell proliferation and steroid hormone receptors in endometrial hyperplasia and early adenocarcinoma.

Authors:  R Punnonen; J Mattila; T Kuoppala; T Koivula
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.